Bottom line
DSIP + Epitalon + Selank is marketed under names including "Circadian Signaling Research Protocol" and "EPIDSINK." The name can refer either to a three-vial kit or to a single 10 mL liquid listing. That kit-versus-vial distinction is material: products supplied separately are not evidence of a compatible co-formulation. No published study of the named set was identified.
No established or recommended human dose. Package format and amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Aureum Peptides, "Circadian Signaling Research Protocol" (2026) | DSIP, Epitalon, Selank | Three-vial kit; component masses not consistently published | Vendor-declared kit; it should not be described as one mixed vial |
| Peptide Products, "EPIDSINK" (2026) | DSIP, Epitalon, Selank | 10 mL liquid; peptide masses not consistently published | Vendor-declared liquid; concentration and identity not independently verified |
"Three-vial kit" and "10 mL liquid" are different product forms. Volume alone does not disclose peptide mass, concentration, identity, or equivalence.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| DSIP | See component monograph | None identified for the named set | None identified |
| Epitalon | See component monograph | None identified for the named set | None identified |
| Selank | See component monograph | None identified for the named set | None identified |
Combination-specific studies
No published peer-reviewed study of "EPIDSINK" or the named three-component research set was identified. A bundled kit is a commercial association, not evidence that simultaneous use or physical mixing has been studied.
Safety and interaction uncertainties
Kit and liquid presentations do not establish the same exposure or formulation.
No combination-specific human safety, interaction, pharmacokinetic, or toxicology data were identified.
Unpublished component masses prevent meaningful comparison between observed listings.
Identity, purity, sterility, concentration, and stability cannot be inferred from packaging language.
Regulatory and product-quality notes
The observed names are vendor-created and are not regulatory or pharmacopoeial standards.
"Protocol" is quoted only as a product name; this atlas does not provide instructions for use.
The cited pages are low-quality market observations and do not establish approval, safety, or suitability for humans.
Evidence gaps
No combination-specific study
No stable definition across kit and liquid formats
No consistently published component masses
No independent analytical or stability assessment
Sources
Aureum Peptides. Circadian Signaling Research Protocol market page. https://aureumpeptides.com/ accessed 2026-08-08.
Peptide Products. EPIDSINK market page. https://peptide-products.com/ accessed 2026-08-08.